Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03559972 · ClinicalTrials.gov registry record · NA

Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

A NA study, sponsored by Allergan.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT03559972: Completed NA study, sponsored by Allergan.

NCT03559972 is a NA study that has completed, run by Allergan. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03559972, a NA study, has completed, sponsored by Allergan.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This study will assess the efficacy and tolerability of two topical regimens (containing cosmetic human fibroblast-derived, physiologically-balanced growth factor combination products (HULK and TNS Essential Serum)

Primary Outcome

Investigator will assess the following parameters on a Griffith's modified 10-point scale (0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, 7 to 9 = Severe)

Interventions

  • OTHER on-label facial injection

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-06-04
Est. Completion 2018-12-03
Phase NA
Allergan

314 total trials

What the finished NCT03559972 record still lists

NCT03559972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which on-label facial injection is the first listed.

NCT03559972 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03559972 about?

NCT03559972 is a clinical study titled "Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections". This study will assess the efficacy and tolerability of two topical regimens (containing cosmetic human fibroblast-derived, physiologically-balanced growth factor combination products (HULK and TNS Essential Serum)

What is the current status of trial NCT03559972?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2018-06-04. Estimated completion is 2018-12-03.

What interventions are being tested in trial NCT03559972?

The interventions under investigation include: on-label facial injection (OTHER).

Who is sponsoring clinical trial NCT03559972?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03559972's enrollment target sits among peer trials

40 1447th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03559972, the US trial registry maintained by the National Library of Medicine. NCT03559972 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.